ALNEV.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:24):

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France...

Stats
Today's Volume	7 992.00
Average Volume	2.19M
Market Cap	97 115.00
EPS	0 ( 2019-10-02 )
Last Dividend	0 ( N/A )
Next Dividend	0 ( N/A )
P/E	0
ATR14	0.00900 (3.10%)

Neovacs SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neovacs SA Financials

Annual	2022
Revenue:	1 112.00
Gross Profit:	-3.43M (-308 866.37 %)
EPS:	-117.60

Q2	2023
Revenue:	102 371
Gross Profit:	-1.95M (-1 906.19 %)
EPS:	-3.06

Q4	2022
Revenue:	-48 888.00
Gross Profit:	-1.68M (3 427.33 %)
EPS:	0

Q2	2022
Revenue:	50 000.00
Gross Profit:	-2.17M (-4 330.63 %)
EPS:	-1 607.61

Financial Reports:

No articles found.

Neovacs SA

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.